AneuRx stent-graft

AneuRx AAAdvantage Stent Graft System

There may be a higher death rate after five years among patients treated for abdominal aortic aneurysms with a Medtronic Inc. device than among those treated through conventional surgical means, according the U.S. Food and Drug Administration.

A public-health notification posted on the FDA’s Web site said the agency was looking at Medtronic’s AneuRx stent-graft system because it is the only currently marketed device that has a significant number of patients who have been examined for at least five years after receiving a device.